Cargando…

Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy

BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun-Jung, Kim, Hyung-Kwan, Kim, Bong-Sung, Han, Kyung-Do, Park, Jun-Bean, Lee, Heesun, Lee, Seung-Pyo, Kim, Yong-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211274/
https://www.ncbi.nlm.nih.gov/pubmed/34138972
http://dx.doi.org/10.1371/journal.pone.0253310
_version_ 1783709449610854400
author Lee, Hyun-Jung
Kim, Hyung-Kwan
Kim, Bong-Sung
Han, Kyung-Do
Park, Jun-Bean
Lee, Heesun
Lee, Seung-Pyo
Kim, Yong-Jin
author_facet Lee, Hyun-Jung
Kim, Hyung-Kwan
Kim, Bong-Sung
Han, Kyung-Do
Park, Jun-Bean
Lee, Heesun
Lee, Seung-Pyo
Kim, Yong-Jin
author_sort Lee, Hyun-Jung
collection PubMed
description BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs. METHODS: Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013–2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke. RESULTS: During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65–0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation. CONCLUSION: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality.
format Online
Article
Text
id pubmed-8211274
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82112742021-06-29 Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy Lee, Hyun-Jung Kim, Hyung-Kwan Kim, Bong-Sung Han, Kyung-Do Park, Jun-Bean Lee, Heesun Lee, Seung-Pyo Kim, Yong-Jin PLoS One Research Article BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs. METHODS: Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013–2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke. RESULTS: During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65–0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation. CONCLUSION: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality. Public Library of Science 2021-06-17 /pmc/articles/PMC8211274/ /pubmed/34138972 http://dx.doi.org/10.1371/journal.pone.0253310 Text en © 2021 Lee et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lee, Hyun-Jung
Kim, Hyung-Kwan
Kim, Bong-Sung
Han, Kyung-Do
Park, Jun-Bean
Lee, Heesun
Lee, Seung-Pyo
Kim, Yong-Jin
Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
title Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
title_full Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
title_fullStr Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
title_full_unstemmed Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
title_short Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
title_sort risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211274/
https://www.ncbi.nlm.nih.gov/pubmed/34138972
http://dx.doi.org/10.1371/journal.pone.0253310
work_keys_str_mv AT leehyunjung riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT kimhyungkwan riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT kimbongsung riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT hankyungdo riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT parkjunbean riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT leeheesun riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT leeseungpyo riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy
AT kimyongjin riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy